CEO Catherine Pickering highlights the strategic impact of appointing two seasoned industry leaders to strengthen iOnctura’s medical and commercial leadership capabilities
On July 24, 2025, iOnctura announced the appointment of two distinguished industry experts to its Board of Directors: Dr. Neil Gallagher, M.D., Ph.D., former Chief Medical Officer at AbbVie and President of R&D at Syndax; and Anthony Mancini, current Chief Global Commercialization Officer at Revolution Medicines.
Q.
What prompted this evolution of the iOnctura Board?
iOnctura is at a pivotal inflection point. We recently initiated several Phase II clinical trials for our lead program, roginolisib, with data readouts expected in the coming year. As we gear up to move into late clinical development and we start to think about expanding the reach of our portfolio through partnerships, it has become clear that expanding the Board with complementary expertise is essential.
Biotech leaders today face increasingly complex challenges – from navigating scientific innovation and regulatory frameworks to managing commercialization dynamics and building stakeholder trust. Bringing new voices to the boardroom with deep domain expertise allows us to not only diversify our skill set but also enrich the breadth of perspectives guiding our next growth phase.
Q.
What strengths do Neil Gallagher and Anthony Mancini bring to the Board?
We’re delighted to welcome Neil and Anthony to the iOnctura Board. Each brings extensive and highly relevant experience that will be critical to achieving our long-term vision.
Dr. Gallagher brings a wealth of oncology development experience, having led global R&D efforts at Syndax and spearheaded programs as Chief Medical Officer at AbbVie. Many of those programs achieved regulatory approval – experience that will be invaluable as we advance our own pipeline.
Anthony Mancini adds deep commercial leadership, currently serving as Chief Gobal Commercialization Officer at Revolution Medicines and formerly as Chief Operating Officer of Genmab. His insight into global drug launches, commercialization strategies, and market readiness will help us prepare for the next stages of company evolution.
In addition to their expertise, both Neil and Anthony possess robust networks across the biotech and pharmaceutical industries. Their longstanding relationships with key opinion leaders, commercial experts and potential partners will not only open doors to new opportunities and collaborations but also ensure iOnctura remains at the forefront of industry developments.
Together, their medical and commercial acumen – bolstered by their unparalleled professional networks – will elevate boardroom discussions, enabling smarter, faster strategic choices.
Q.
How does this align with iOnctura’s future ambitions?
As we work to develop treatments for patients with hard-to-treat and underserved cancers, success will depend on our ability to execute across development, regulatory, and commercialization pathways. In a highly competitive oncology market, precision in execution is just as critical as innovation.
Our strengthened Board brings decades of collective experience in advancing oncology drugs from bench to bedside – building platforms, launching products, and scaling biotechs globally. These targeted additions position iOnctura to not only meet the moment but lead the future.
